Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16116
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBeckmann, Kerri R-
dc.contributor.authorO'Callaghan, Michael E-
dc.contributor.authorRuseckaite, Rasa-
dc.contributor.authorKinnear, Ned-
dc.contributor.authorMiller, Caroline-
dc.contributor.authorEvans, Sue-
dc.contributor.authorRoder, David M-
dc.contributor.authorMoretti, Kim-
dc.date2016-08-04-
dc.date.accessioned2016-08-10T02:01:13Z-
dc.date.available2016-08-10T02:01:13Z-
dc.date.issued2017-06-
dc.identifier.citationBJU International 2017; 119(6): 862-871en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16116-
dc.description.abstractOBJECTIVE: To compare clinical features, treatments and outcomes in men with non-metastatic prostate cancer (PCa) according to whether they were referred for symptoms or elevated prostate specific antigen (PSA). PATIENTS AND METHODS: This study used data from the South Australia Prostate Cancer Clinical Outcomes Collaborative database; a multi-institutional clinical registry covering both the public and private sectors. Participants included all non-metastatic cases from 1998-2013 referred for urinary/prostatic symptoms or elevated PSA. Multivariate Poisson regression was used to identify characteristics associated with symptomatic presentation and compare treatments according to reason for referral. Outcomes (i.e. overall survival, PCa survival, metastatic-free survival and disease-free survival) were compared using multivariate Cox proportional hazards and competing risk regression. RESULTS: Our analytic cohort consisted of 4841 men with localised PCa. Symptomatic men had lower risk disease (IR= 0.70, CI 0.61-0.81 for high vs low risk), fewer radical prostatectomies (IR=0.64 CI 0.56-0.75) and less radiotherapy (IR=0.86, CI 0.77-0.96) than men presenting with elevated PSA. All-cause mortality (HR=1.31, CI 1.16-1.47), disease-specific mortality (HR=1.42, CI 1.13-1.77) and risk of metastases (HR=1.36, CI 1.13-1.64) were higher for men presenting with symptoms, after adjustment for other clinical characteristics. However, risk of disease progression did not differ (HR=0.90, CI 0.74-1.07) amongst those treated curatively. Subgroup analyses indicated poorer PCa survival for symptomatic referral among men undergoing radical prostatectomy (HR=3.4, CI 1.3-8.8), those over 70 years (HR=1.4, CI 1.0-1.8), private patients (HR=2.1, CI 1.3-3.3), those diagnosed via biopsy (HR=1.3, CI 1.0-1.7) and those diagnosed before 2006 (HR=1.6, CI 1.1.2-1.7). CONCLUSION: Our results suggest that symptomatic presentation may be an independent negative prognostic indicator for PCa survival. More complete assessment of disease grade and extent, more definitive treatment and increased post-treatment monitoring among symptomatic cases may improve outcomes. Further research to determine any pathophysiological basis for poor outcomes in symptomatic men is warranted. This article is protected by copyright. All rights reserved.en_US
dc.subjectProstate canceren_US
dc.subjectLower urinary tract symptomsen_US
dc.subjectOncological outcomesen_US
dc.titleProstate cancer outcomes for men who present with symptoms at diagnosisen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBJU Internationalen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationCentre for Population Health Research, School of Health Science, University of South Australia, Adelaide, Australiaen_US
dc.identifier.affiliationSouth Australian Prostate Cancer Clinical Outcomes Collaborative, Department of Urology, Repatriation General Hospital, Daw Park, South Australia, Australiaen_US
dc.identifier.affiliationFlinders Centre for Innovation in Cancer, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationDiscipline of Medicine and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Urology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationPopulation Health Research Group, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationDepartment of Urology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27489140en_US
dc.identifier.doi10.1111/bju.13622en_US
dc.contributor.corpauthorSouth Australian Prostate Cancer Clinical Outcomes Collaborative-
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.